We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
I Agree
  • Arch Biopartners to Proceed with Metablok Trial for COVID-19 americanpharmaceuticalreview
    June 28, 2020
    Arch Biopartners announced the U.S. Food and Drug Administration (FDA) has granted permission to the Company to proceed with a Phase II trial in the U.S. for its lead drug Metablok (LSALT peptide) to prevent acute lung and kidney injury experienced by ...
  • Arch Biopartners Expands Primary Endpoint of COVID-19 Trial americanpharmaceuticalreview
    May 26, 2020
PharmaSources Customer Service